Clinical Significance of Pretreatment C-Reactive Protein in Patients with Advanced Nonsquamous, Non-Small Cell Lung Cancer Who Received Gefitinib

Oncology ◽  
2010 ◽  
Vol 79 (5-6) ◽  
pp. 355-362 ◽  
Author(s):  
Katsuhiro Masago ◽  
Shiro Fujita ◽  
Yosuke Togashi ◽  
Young Hak Kim ◽  
Yukimasa Hatachi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Significance ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
C Reactive Protein ◽  
Small Cell Lung ◽  
Reactive Protein

Prognostic Significance of Perioperative C-Reactive Protein in Resected Non-Small Cell Lung Cancer

2020 ◽  
Vol 32 (4) ◽  
pp. 1046-1055 ◽  
Author(s):  
Satoru Okada ◽  
Masanori Shimomura ◽  
Hiroaki Tsunezuka ◽  
Satoshi Teramukai ◽  
Shunta Ishihara ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Prognostic Significance ◽  
Small Cell ◽  
C Reactive Protein ◽  
Small Cell Lung ◽  
Reactive Protein

scholarly journals Preresection serum C-reactive protein measurement and survival among patients with resectable non–small cell lung cancer

2011 ◽  
Vol 142 (5) ◽  
pp. 1161-1167 ◽  
Author(s):  
Marco Alifano ◽  
Pierre E. Falcoz ◽  
Valérie Seegers ◽  
Nicolas Roche ◽  
Olivier Schussler ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
C Reactive Protein ◽  
Small Cell Lung ◽  
Reactive Protein ◽  
Protein Measurement

Monitoring C-reactive protein facilitates early discontinuation of immune oncology without compromising outcomes in stage IV non-small cell lung cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e21107-e21107
Author(s):  
Tyler Fugere ◽  
Ples Spradley ◽  
Ahmad Mazen Safar
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Stage Iv ◽  
Progression Free Survival ◽  
Small Cell ◽  
C Reactive Protein ◽  
Small Cell Lung ◽  
Free Survival ◽  
Reactive Protein

e21107 Background: C-Reactive Protein (CRP) is a non-specific inflammatory marker and reflects tissue destruction seen in metastatic cancer (ca). We have observed a tight correlation with CRP trends mirroring ca activity, hence it may prove to be a valuable marker to monitor response to Immuno-Oncology (IO) in non-small cell lung cancer (NSCLC) patients (pts). Once CRP levels stabilized, IO discontinuation was offered, and consenting pts were closely observed. This strategy resulted in shortened IO duration and impressive treatment-free progression-free survival (tf-PFS). We sought to examine the validity of this strategy using the rate of return to any form of ca therapy within 6 months after stopping IO. Methods: We analyzed all pts of a single provider since 2016 with stage IV NSCLC who had CRP checked while on IO, totaling 23 pts. We excluded pts who stopped IO for reasons besides stable CRP values (5 progressed on IO, 3 died while on IO, 1 had side effects, 1 stopped for a clinical trial, 1 opted to complete 2 years of IO, and 2 are still on IO). Of the remaining 10 patient cohort, all pts were males treated at the VA with ages between 56-75 years at diagnosis. 50% of the cohort had adenocarcinoma and 50% had squamous cell carcinoma. Results: Using the CRP trend to shorten the duration of IO resulted in durable drug-free holidays with none of the cohort returning to any form of ca therapy within 6 months and comparable rates of overall survival (OS) despite shorter IO duration. In KEYNOTE-042, the median OS for pts on the pembrolizumab arm was 16.7 months in the overall population and 20 months in the TPS ≥50% subgroup. Pts were treated for up to 35 months. In our cohort, median OS was 38 months, with all pts currently still alive, and median number of doses of IO was 9 cycles, or approximately 7 months. Our pts had ongoing progression free survival (PFS) after stopping treatment, which we report as tf-PFS. The median tf-PFS of our cohort was 23.5 months. Conclusions: In pts with stage IV NSCLC treated with IO, CRP appears promising as a marker to tailor IO therapy addressing tumor and clinical heterogeneity. Responding pts with stable CRP levels can be safely taken off IO. CRP should be monitored with stable values indicating continued PFS. tf-PFS rather than PFS may serve as a surrogate for cure and carries significant impact for pts financially, socially, and psychologically. [Table: see text]

Postoperative C-reactive Protein Is a Predictive Biomarker for Survival After Non-small Cell Lung Cancer Resection

2019 ◽  
Vol 39 (4) ◽  
pp. 2193-2198 ◽  
Author(s):  
SHUICHI SHINOHARA ◽  
RYO OTSUKI ◽  
TAKAMITSU ONITSUKA ◽  
KAZUHIKO MACHIDA ◽  
MASAKI MATSUO ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Predictive Biomarker ◽  
Small Cell ◽  
C Reactive Protein ◽  
Small Cell Lung ◽  
Cancer Resection ◽  
Reactive Protein

scholarly journals Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer

2010 ◽  
Vol 102 (7) ◽  
pp. 1113-1122 ◽  
Author(s):  
B Gagnon ◽  
M Abrahamowicz ◽  
Y Xiao ◽  
M-E Beauchamp ◽  
N MacDonald ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Prognostic Value ◽  
Small Cell ◽  
C Reactive Protein ◽  
Small Cell Lung ◽  
Reactive Protein ◽  
Flexible Modeling

Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer

Lung Cancer ◽  
2006 ◽  
Vol 53 (1) ◽  
pp. 97-101 ◽  
Author(s):  
J. Mark Jones ◽  
Niall C. McGonigle ◽  
Martin McAnespie ◽  
Gordon W. Cran ◽  
Alastair N. Graham
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Plasma Fibrinogen ◽  
C Reactive Protein ◽  
Small Cell Lung ◽  
Reactive Protein

Role of preoperative blood markers as prognostic factors for lung cancer surgery

2019 ◽  
Vol 27 (4) ◽  
pp. 288-293 ◽  
Author(s):  
Umar Imran Hamid ◽  
Reza Al-Saudi ◽  
Ian Paul ◽  
Alastair Graham
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Nodal Metastasis ◽  
Small Cell ◽  
Plasma Fibrinogen ◽  
Clinical Staging ◽  
C Reactive Protein ◽  
Small Cell Lung ◽  
Reactive Protein

Objective This study was undertaken to assess the potential value of preoperative blood components as prognostic markers of outcome after lung cancer resection, and hence their potential to aid in the selection of patients for curative surgery. Methods This was a single-center study on 313 patients who underwent surgery for non-small-cell lung cancer from 2006 to 2008. Data were analyzed retrospectively from a prospectively maintained thoracic database. Preoperative blood results including plasma fibrinogen levels, serum C-reactive protein, hemoglobin concentration, and platelet count were included in the analysis. Results The mean age was 75 years, and 40% of the patients were females. The most common resection was lobectomy in 68% of patients, followed by pneumonectomy, wedge resection, and segmentectomy in 18%, 10%, and 1.6%, respectively. Patients with abnormal C-reactive protein, fibrinogen, and hemoglobin levels had a worse overall survival. Large tumor size and nodal metastasis on clinical staging was also associated with poor survival. However, on Cox regression analysis, plasma fibrinogen and nodal metastasis were the only independent predictors of survival after lung resection. Conclusions Among the different blood markers, elevated preoperative plasma fibrinogen was an independent marker of reduced survival in patients with resected non-small-cell lung cancer, and its value in selecting patients who may benefit from surgery needs further investigation.

Sign in / Sign up

Export Citation Format

Share Document